Quince Therapeutics (QNCX) Depreciation & Amortization (CF) (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Depreciation & Amortization (CF) of $36000.0 for Q1 2026, up 12.5% year-over-year from $32000.0 in Q1 2025, and down 7.69% quarter-over-quarter from $39000.0 in Q4 2025.
Quince Therapeutics (QNCX) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
Quince Therapeutics' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $36000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 12.5% year-over-year to $36000.0; the TTM figure through Mar 2026 stood at $146000.0 (down 17.98% YoY), while the FY2025 annual figure was $142000.0, down 23.66% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $36000.0, down from $39000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $304000.0 in Q4 2023, with the low at $1000.0 in Q2 2023.
- The 5-year median for Depreciation & Amortization (CF) is $38500.0 (2022), against an average of $55625.0.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) plunged 98.81% in 2023, then surged 4300.0% in 2024.
- Quince Therapeutics' Depreciation & Amortization (CF) stood at $42000.0 in 2022, then soared by 623.81% to $304000.0 in 2023, then tumbled by 94.74% to $16000.0 in 2024, then jumped by 143.75% to $39000.0 in 2025, then slipped by 7.69% to $36000.0 in 2026.
- Business Quant data shows QNCX's Depreciation & Amortization (CF) at $36000.0 in Q1 2026, $39000.0 in Q4 2025, and $36000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 41,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36,000.00 |
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 39,000.00 |
| Dec 31, 2025 | 39,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | 16,000.00 |
| Dec 31, 2024 | 16,000.00 |
| Sep 30, 2024 | 86,000.00 |
| Sep 30, 2024 | 86,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Dec 31, 2023 | 304,000.00 |
| Dec 31, 2023 | 304,000.00 |